explore -WSS

explore

author：comprehensive 2025-10-01 01:51:06 - browse：5524

An illustrated portrait of Eli Lilly's David Ricks and Skovronsky – biotech and pharma coverage from STAT — Eli Lilly CEO David Ricks (left) and Chief Scientific Officer Daniel S. Skovronsky Molly Ferguson for STAT

The partnership that would shape Eli Lilly into one of the biggest success stories in the pharmaceutical industry began with conversations around a relatively minor acquisition.

At the time, David Ricks was running Lilly’s U.S. business and was part of the team charged with evaluating Avid Radiopharmaceuticals, which Lilly would go on to purchase in 2010 for a paltry $300 million — couch change for a multibillion-dollar firm. But what struck Ricks was not the company’s technology, for imaging Alzheimer’s plaques, but Avid’s CEO, Daniel S. Skovronsky.

“Dan’s different,” Ricks told STAT. “I had this sense immediately. Some people get in biotech for the cha-ching.” Skovronsky turned out to be a secret weapon. Within six months, Ricks had been promoted to run Lilly’s biomedicine unit and Skovronsky was working for him.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi

WSS

Organ aging and disease risk measured by new blood test

Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

Trump team launching legal defense fund to help pay legal bills

Despite FDA concern, risk that CAR

What don’t we know about an Alzheimer’s drug side effect?

Trump PAC spent more than $40M on legal bills this year as his charges mount: Sources

entertainment

explore

focus

Apple is now the first public company to be valued at $3 trillion

HCA says smaller share of spending going to labor

Malaria cases in Florida and Texas: Here’s what you need to know

What don’t we know about an Alzheimer’s drug side effect?

Anesthesiologist group: stop taking Ozempic before surgery

Will the market for weight loss drugs really reach $100 billion?

Walensky prepares to leave CDC — and Congress — behind

As biotech industry slumps, bioscience job market is upside down

Medicare proposal to cover medical devices draws a mixed reaction

China demands US invite Hong Kong leader to economic meeting, adding to strains over crackdown

focus

'Weather

30 years of 'Listening to Prozac'

With clinical trial data readouts, here's how to spot spin

Organ aging and disease risk measured by new blood test

Sudan conflict brings new atrocities to Darfur as militias kill, rape, burn homes in rampages

Despite FDA concern, risk that CAR

knowledge

focus

leisure time

hotspot